RBQM is redefining how clinical trials are designed, enabling smarter, more resilient research.
Collaborating Under ICH E6 (R3)
Explore how sponsors and CROs must rethink collaboration and embed quality into every layer of trial execution.
Why ICH E6 R3 Matters for Clinical Trials
Explore how E6 (R3) reshapes trial design, oversight, and culture, and why the industry must be ready to respond.
What is ICH E6 (R3)?
ICH E6 (R3) sets a new global benchmark for Good Clinical Practice, modernizing oversight with principle-based, risk-driven, and digitally enabled trial design.
The Quality Issue – July 2025
ICH E6(R3) is now effective in the EU, marking a pivotal shift in clinical trial oversight. This issue breaks down what it means and how to stay ahead.
TRI launches major overhaul of OPRA-CM
TRI’s reimagined OPRA-CM platform delivers on the true promise of RBQM, cutting through complexity to enable smarter, faster, and more focused centralized monitoring.
The Quality Issue – May 2025
In this edition, we mark National Clinical Trials Day, spotlight new Tufts CSDD research on monitoring trends, and share must-attend events.
Lessons from London
This blog explores how clinical research leaders are navigating post-Covid uncertainty, shifting buyer expectations, and the growing need for authenticity, trust, and AI-driven value.
The Quality Issue – April 2025
From Vancouver to London, this edition highlights must-attend RBQM events that offer fresh insights, regulatory updates, and real-world strategies to elevate your clinical trial oversight.
SCDM – April 2025
We’re heading to Brussels for SCDM 2025 EMEA! Visit TRI at Booth 21 to discover how our reimagined OPRA-CM platform is transforming centralized monitoring and driving RBQM success.